Is Point-of-Care Hepatitis C Virus Testing Too Expensive?
RNA testing carries substantial cost burden for hospitals, study finds
Clinical Scorecard: Is Point-of-Care Hepatitis C Virus Testing Too Expensive?
At a Glance
Category Detail
Condition Hepatitis C Virus (HCV) Key Mechanisms Point-of-care RNA testing vs. traditional two-step testing Target Population Safety-net populations in emergency departments Care Setting Emergency departments and outpatient clinics
Key Highlights
Point-of-care RNA testing could increase hospital laboratory costs by up to 260%. Emergency department testing increased 682% from 2017 to 2024. HCV antigen testing is a cost-effective alternative, adding only $11,494 in annual costs. Guideline-Based Recommendations
Diagnosis
Consider point-of-care RNA testing for immediate treatment initiation. Management
Evaluate cost implications of point-of-care testing versus traditional methods. Monitoring & Follow-up
Track antibody positivity rates in different care settings. Risks
Increased laboratory costs may impact other testing services. Patient & Prescribing Data
Patients diagnosed with HCV in emergency departments.
Immediate treatment initiation is possible with rapid RNA tests.
Clinical Best Practices
Implement targeted deployment strategies for HCV testing. Consider HCV antigen testing as a cost-effective alternative. Related Resources & Content
